NO992426L - N- (aryl / heteroaryl) amino acid derivatives, pharmaceutical compositions comprising the same, and methods for inhibiting <beta> -amyloid peptide release and / or its synthesis using such compounds - Google Patents
N- (aryl / heteroaryl) amino acid derivatives, pharmaceutical compositions comprising the same, and methods for inhibiting <beta> -amyloid peptide release and / or its synthesis using such compoundsInfo
- Publication number
- NO992426L NO992426L NO992426A NO992426A NO992426L NO 992426 L NO992426 L NO 992426L NO 992426 A NO992426 A NO 992426A NO 992426 A NO992426 A NO 992426A NO 992426 L NO992426 L NO 992426L
- Authority
- NO
- Norway
- Prior art keywords
- synthesis
- pharmaceutical compositions
- compounds
- amyloid peptide
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Det er omtalt forbindelser som inhiberer 13-amyloidpeptidfrigivning og/eller dets syntese, og følgelig kan anvendes for å behandle Alzheimers sykdom. Også omtalt er farmasøytiske sammensetninger som omfatter en forbindelse som inhiberer 15- amyloidpeptidfrigivning og/eller dets syntese så vel som fremgangsmåter for å behandle Alzheimers sykdom både profylaktisk og terapeutisk med slike farmasøytiske sammensetningerCompounds that inhibit 13-amyloid peptide release and / or its synthesis are disclosed and can therefore be used to treat Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits 15-amyloid peptide release and / or its synthesis as well as methods of treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75533496A | 1996-11-22 | 1996-11-22 | |
PCT/US1997/018704 WO1998022493A2 (en) | 1996-11-22 | 1997-11-20 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS |
Publications (2)
Publication Number | Publication Date |
---|---|
NO992426D0 NO992426D0 (en) | 1999-05-20 |
NO992426L true NO992426L (en) | 1999-06-30 |
Family
ID=25038718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO992426A NO992426L (en) | 1996-11-22 | 1999-05-20 | N- (aryl / heteroaryl) amino acid derivatives, pharmaceutical compositions comprising the same, and methods for inhibiting <beta> -amyloid peptide release and / or its synthesis using such compounds |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0942923A2 (en) |
JP (1) | JP2001519769A (en) |
CN (1) | CN1237978A (en) |
AU (1) | AU5354398A (en) |
BR (1) | BR9714358A (en) |
CA (1) | CA2270876A1 (en) |
HU (1) | HUP0001383A3 (en) |
ID (1) | ID22275A (en) |
IL (1) | IL129477A0 (en) |
NO (1) | NO992426L (en) |
NZ (1) | NZ335157A (en) |
TR (1) | TR199901132T2 (en) |
WO (1) | WO1998022493A2 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ525513A (en) | 1998-08-07 | 2004-09-24 | Pont Pharmaceuticals Du | Succinoylamino lactams as inhibitors of Abeta protein production |
HRP990246A2 (en) | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
WO2000019210A2 (en) | 1998-09-30 | 2000-04-06 | Elan Pharmaceuticals, Inc. | Determining the mechanism of beta-amyloid peptide generation |
US6737038B1 (en) | 1998-11-12 | 2004-05-18 | Bristol-Myers Squibb Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
CN1636011A (en) | 1998-12-24 | 2005-07-06 | 杜邦药品公司 | Succinoylamino lactams as inhibitors and as a beta protein production |
US6960576B2 (en) | 1999-09-13 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production |
US6503902B2 (en) | 1999-09-13 | 2003-01-07 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production |
WO2001027108A1 (en) | 1999-10-08 | 2001-04-19 | Bristol-Myers Squibb Pharma Company | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
EP1261610A2 (en) | 2000-02-17 | 2002-12-04 | Bristol-Myers Squibb Pharma Company | Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production |
IL151576A0 (en) | 2000-04-03 | 2003-04-10 | Bristol Myers Squibb Pharma Co | Cyclic lactams as inhibitors of a-beta protein production |
EP1268434A1 (en) | 2000-04-03 | 2003-01-02 | Bristol-Myers Squibb Pharma Company | Cyclic lactams as inhibitors of a-beta protein production |
EP1289966A1 (en) | 2000-04-11 | 2003-03-12 | Bristol-Myers Squibb Pharma Company | SUBSTITUTED LACTAMS AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION |
WO2001087354A2 (en) | 2000-05-17 | 2001-11-22 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands for diagnostic imaging |
BR0106717A (en) | 2000-06-01 | 2002-04-16 | Bristol Myers Squibb Pharma Co | Compounds, pharmaceutical composition and uses of innovative lactam compounds |
US6432944B1 (en) | 2000-07-06 | 2002-08-13 | Bristol-Myers Squibb Company | Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives |
PT2264018E (en) | 2000-08-24 | 2015-06-03 | Univ Pittsburgh | Thioflavin derivatives for use in the diagnosis of alzheimer's disease |
US7270800B2 (en) | 2000-08-24 | 2007-09-18 | University Of Pittsburgh | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
CN1263750C (en) | 2000-12-13 | 2006-07-12 | 惠氏 | Heterocyclic sulfonamide inhibitors of beta amyloid production |
US6657070B2 (en) | 2000-12-13 | 2003-12-02 | Wyeth | Production of chirally pure α-amino acids and N-sulfonyl α-amino acids |
CH698246B1 (en) * | 2001-12-20 | 2009-06-30 | Hoffmann La Roche | Test to identify inhibitors of beta secretases. |
DE10306202A1 (en) | 2003-02-13 | 2004-08-26 | Grünenthal GmbH | 2-(hetero)aryl-2-(N-((hetero)aryl)-amino)-acetic acid derivatives useful e.g. for treating anxiety, inflammation, allergy, depression, diarrhea or especially pain is NMDA antagonist |
PT1611115E (en) * | 2003-03-14 | 2012-12-07 | Univ Pittsburgh | Benzothiazole derivative compounds, compositions and uses |
CL2004000647A1 (en) | 2003-03-31 | 2005-02-04 | Wyeth Corp | COMPOUNDS DERIVED FROM SULFONAMIDE HETEROCICLES CONTAINING FLUORO AND TRIFLUORO RENT; PHARMACEUTICAL COMPOSITION; PHARMACEUTICAL KIT; PREPARATION PROCEDURE; AND ITS USE AS BETA AMILOID INHIBITORS TO TREAT ALZHEIMER, ANGIOPATIA AM |
EP2511267A1 (en) | 2003-06-05 | 2012-10-17 | Elan Pharmaceuticals Inc. | 3-((n-acylated aminoacyl)amino)pyrazoles as inhibitors of beta-amyloid peptide production useful for the treatment of alzheimer's disease |
US8236282B2 (en) | 2003-08-22 | 2012-08-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | Benzothiazole derivative compounds, compositions and uses |
EP1709003B1 (en) | 2004-01-16 | 2009-09-23 | Wyeth | Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole |
JP4805909B2 (en) | 2004-03-03 | 2011-11-02 | スミスクライン ビーチャム コーポレーション | Aniline derivatives as selective androgen receptor modulators |
WO2006113552A2 (en) * | 2005-04-15 | 2006-10-26 | Smithkline Beecham Corporation | Cyanoarylamines |
CN100999546B (en) * | 2007-01-11 | 2010-08-11 | 清华大学 | Polypeptide compound with aza-containing heterocyclic modification and its application |
WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
CN111777571B (en) * | 2020-06-28 | 2023-07-11 | 武汉药明康德新药开发有限公司 | Synthesis method of chiral 2-amino-3- (1, 3-benzothiazole-2-yl) propionic acid hydrochloride |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE211129T1 (en) * | 1993-10-01 | 2002-01-15 | Merrell Pharma Inc | INHIBITORS OF BETA-AMYLOID PROTEIN PRODUCTION |
US5872101A (en) * | 1995-01-06 | 1999-02-16 | Sibia Neurosciences, Inc. | Methods of treating neurodegenerative disorders using protease inhibitors |
-
1997
- 1997-11-20 WO PCT/US1997/018704 patent/WO1998022493A2/en not_active Application Discontinuation
- 1997-11-20 CN CN97199776A patent/CN1237978A/en active Pending
- 1997-11-20 AU AU53543/98A patent/AU5354398A/en not_active Abandoned
- 1997-11-20 TR TR1999/01132T patent/TR199901132T2/en unknown
- 1997-11-20 JP JP52364998A patent/JP2001519769A/en active Pending
- 1997-11-20 BR BR9714358A patent/BR9714358A/en not_active IP Right Cessation
- 1997-11-20 ID IDW990395A patent/ID22275A/en unknown
- 1997-11-20 HU HU0001383A patent/HUP0001383A3/en unknown
- 1997-11-20 NZ NZ335157A patent/NZ335157A/en unknown
- 1997-11-20 EP EP97950576A patent/EP0942923A2/en not_active Withdrawn
- 1997-11-20 CA CA002270876A patent/CA2270876A1/en not_active Abandoned
- 1997-11-20 IL IL12947797A patent/IL129477A0/en unknown
-
1999
- 1999-05-20 NO NO992426A patent/NO992426L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HUP0001383A3 (en) | 2001-11-28 |
CN1237978A (en) | 1999-12-08 |
WO1998022493A3 (en) | 1998-07-23 |
NZ335157A (en) | 2001-01-26 |
TR199901132T2 (en) | 1999-08-23 |
EP0942923A2 (en) | 1999-09-22 |
ID22275A (en) | 1999-09-23 |
IL129477A0 (en) | 2000-02-29 |
AU5354398A (en) | 1998-06-10 |
NO992426D0 (en) | 1999-05-20 |
HUP0001383A1 (en) | 2001-05-28 |
BR9714358A (en) | 2000-03-21 |
JP2001519769A (en) | 2001-10-23 |
CA2270876A1 (en) | 1998-05-28 |
WO1998022493A2 (en) | 1998-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO992426L (en) | N- (aryl / heteroaryl) amino acid derivatives, pharmaceutical compositions comprising the same, and methods for inhibiting <beta> -amyloid peptide release and / or its synthesis using such compounds | |
NO992463L (en) | N- (aryl / heteroarylacetyl) amino acid esters, pharmaceutical compositions including the same, and methods for inhibiting <beta> -amyloid peptide release and / or its synthesis using such compounds | |
NO992368L (en) | Methods and Compounds for Inhibiting <beta> -amyloid Release and / or its Synthesis | |
NO994016L (en) | Heterocyclic Compounds and Their Use for Inhibition of <beta> Amyloid Peptide | |
CA2367017A1 (en) | Inhibitors of impdh enzyme | |
BR0212787A (en) | Pharmaceutically acceptable compound or salt thereof, methods of treating or preventing disease and preparing a compound, use of a compound or salt, and pharmaceutical composition | |
BR0213139A (en) | Compound, method of treating or preventing disease and preparing a compound, use of a compound and pharmaceutical composition | |
BR0314071A (en) | 1,3-Diamino-2-hydroxypropane prodrug derivatives | |
BR0211119A (en) | Compound, method of treating a patient who has, or preventing a patient from catching, a disease or condition, use of a compound, and method for making a compound | |
BRPI0409624A (en) | Benzamide 2-hydroxy-3-diaminoalkanes | |
BR0211122A (en) | Compound, methods for treating or preventing disease and for making a compound, intermediate, and use of a compound or salt | |
BR9814643A (en) | Aromatic hydroxamic acid sulfone metalloprotease inhibitor | |
NO20003018L (en) | Triazinangiogenese inhibitors | |
BR0210391A (en) | Compound, methods of treating a patient who has or prevent a patient from contracting a disease or condition and preparing a compound, and, using a compound | |
DK0468012T3 (en) | 17beta-substituted 4-aza-5alpha-androstan-3-one derivatives and process for their preparation | |
NO991494L (en) | <beta> -sulfonylhydroxamic acids as matrix metalloproteinase inhibitors | |
BR0211118A (en) | Compound, methods for treating or preventing disease and for making a compound, intermediate, and use of a compound or salt | |
NO20000231L (en) | Dolastatin-15 derivatives | |
BR0316629A (en) | Substituted urea and carbamates | |
HUP0102255A2 (en) | Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use | |
WO1998022441A3 (en) | N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions, and methods for inhibiting beta-amyloid peptide and/or its synthesis | |
BR0115424A (en) | Compound, pharmaceutical composition, methods for inhibiting the release of beta-amyloid peptide and / or its synthesis, for treating alzheimer's disease, for preventing alzheimer's disease, and for inhibiting the progress of alzheimer's disease, processes for preparing the compound , and to prepare lactams, and, use of compound | |
CA2266759A1 (en) | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase | |
BR0314180A (en) | Substituted Aminoethers for the Treatment of Alzheimer's Disease | |
BR0211121A (en) | Compound, methods for treating or preventing disease and for making a compound, intermediate, and use of a compound or salt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |